» Articles » PMID: 12963127

Differentiation-dependent Expression of Signal Transducers and Activators of Transcription (STATs) Might Modify Responses to Growth Factors in the Cancers of the Head and Neck

Overview
Journal Cancer Lett
Specialty Oncology
Date 2003 Sep 10
PMID 12963127
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Overexpression of the epidermal growth factor receptor (EGFR) in the cancers of the head and neck is well demonstrated. In addition, copy numbers of the EGFR mRNA were significantly higher in poorly differentiated tumors than in tumors that had a differentiated phenotype. Studies by others also showed that the constitutively activated signal transducer and activator of transcription-3 (STAT3), but not STAT1, is required for EGFR-mediated cell growth. Our aim was to reveal if STAT expression is differentiation-dependent and thus, might respond to exogenous stimuli in a differentiation-dependent manner. Both reverse transcription-polymerase chain reaction (RT-PCR) and immunohistochemistry revealed that expression of STAT1 was high in well/moderately differentiated tumors in vivo. In contrast, STAT3 was expressed in poorly differentiated tumors. In vitro experiments showed that differentiated primary oral keratinocytes expressed higher levels of STAT1, but lower levels of STAT3 than did their undifferentiated counterparts. Epidermal growth factor treatment of oral keratinocytes with various degrees of differentiation showed the maximal induction of cyclin D1 in undifferentiated cells. Our findings suggest that the level of differentiation might modulate the outcome of EGFR signaling (i.e. cyclin D1 transcription), due to the differentiation-associated intracellular balance of transcriptional regulators (STAT1 versus STAT3).

Citing Articles

The multifaceted role of STAT3 pathway and its implication as a potential therapeutic target in oral cancer.

Khatoon E, Hegde M, Kumar A, Daimary U, Sethi G, Bishayee A Arch Pharm Res. 2022; 45(8):507-534.

PMID: 35987863 DOI: 10.1007/s12272-022-01398-y.


Nuclear Expression of p-STAT3 Is Associated with Poor Prognosis in ER(-) Breast Cancer.

Nakagawa T, Oda G, Kawachi H, Ishikawa T, Okamoto K, Uetake H Clin Pract. 2022; 12(2):157-167.

PMID: 35314590 PMC: 8938801. DOI: 10.3390/clinpract12020020.


Repression of GPRC5A is associated with activated STAT3, which contributes to tumor progression of head and neck squamous cell carcinoma.

Liu S, Ye D, Wang T, Guo W, Song H, Liao Y Cancer Cell Int. 2017; 17:34.

PMID: 28270740 PMC: 5335824. DOI: 10.1186/s12935-017-0406-x.


Overcoming resistance of targeted EGFR monotherapy by inhibition of STAT3 escape pathway in soft tissue sarcoma.

Wang X, Goldstein D, Crowe P, Yang M, Garrett K, Zeps N Oncotarget. 2016; 7(16):21496-509.

PMID: 26909593 PMC: 5008301. DOI: 10.18632/oncotarget.7452.


Anti-epidermal growth factor receptor therapy in head and neck squamous cell carcinoma: focus on potential molecular mechanisms of drug resistance.

Boeckx C, Baay M, Wouters A, Specenier P, Vermorken J, Peeters M Oncologist. 2013; 18(7):850-64.

PMID: 23821327 PMC: 3720640. DOI: 10.1634/theoncologist.2013-0013.